照护现场传染病检查市场规模、份额、趋势和成长分析报告（2026-2034年）

预计照护现场传染病检查市场规模将从 2025 年的 184.2 亿美元成长到 2034 年的 285.1 亿美元，2026 年至 2034 年的复合年增长率为 4.97%。

随着感染疾病的增加，对快速、准确的诊断解决方案的需求日益增长，全球照护现场（POC​​）传染病检查市场预计将显着增长。新冠肺炎疫情凸显了及时检测在控制疫情传播和有效管理公共卫生的重要性。即时检测的优点在于可在数分钟内提供结果，使医护人员能够迅速做出明智的决策并启动适当的治疗。随着人们越来越重视感染疾病的早期发现和预防，即时检测解决方案的普及预计将加速，从而推动这一重要市场的创新和投资。

此外，技术进步可望彻底改变即时传染病检查领域。分子诊断、微流体和生物感测器的整合正在提高检测的灵敏度和特异性，从而能够检测包括细菌、病毒和寄生虫在内的多种病原体。同时，可在从诊所到偏远地区等各种环境下运行的便捷型设备的开发，正在扩大检测的覆盖范围。随着医疗系统日益重视分散式检查方法，对能够即时提供准确结果的创新即时检测解决方案的需求将持续成长。

此外，对个人化医疗的日益重视以及对全球健康倡议的日益关注预计将塑造即时传染病检查市场的未来。随着医疗服务提供者寻求根据患者的个别需求量身定制治疗方案，对能够指南临床决策的快速诊断工具的需求变得至关重要。即时检测顺应了这一趋势，使医务人员能够快速评估患者病情并相应地调整治疗方案。此外，旨在对抗感染疾病（尤其是在资源匮乏地区）的全球健康倡议正在推动对可在各种环境下部署的即时检测技术的投资。诊断设备製造商、医疗机构和公共卫生机构之间的合作对于推动这些解决方案的实施至关重要，并确保即时传染病检查市场保持敏捷性，能够应对不断涌现的健康挑战。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球照护现场传染病检查市场（依技术划分）

• 市场分析、洞察与预测
• 侧向流动免疫检测
• 凝集试验
• 流通式检测/免疫浓缩试验
• 分子诊断
• 其他的

5. 全球照护现场传染病检查市场（依疾病分类）

• 市场分析、洞察与预测
• HIV POC
• 困难梭状芽孢桿菌传染病
• HBV POC
• 肺炎或链球菌感染疾病
• 呼吸道融合细胞病毒（RSV）即时侦测
• HPV POC
• 流感/即时检测
• HCV POC
• MRSA POC
• 结核病和抗药性结核病的即时检测
• HSV POC
• 新型冠状病毒感染疾病（COVID-19）
• 其他的

6. 全球照护现场传染病检查市场（依最终用途划分）

• 市场分析、洞察与预测
• 诊所
• 医院
• 家
• 生活协助设施
• 检查机构

7. 全球照护现场传染病检查市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第八章 竞争情势

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第九章：公司简介

• 主要公司的市占率分析
• 公司简介
  • Abbott
  • Thermo Fisher Scientific Inc
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers
  • Becton
  • Dickinson & Company
  • Chembio Diagnostics Inc
  • Trinity Biotech
  • Cardinal Health
  • Quest Diagnostics Incorporated
  • Bio-Rad Laboratories Inc
  • BioMAfA（C）Rieux SA
  • Sight Diagnostics Ltd
  • Gene POC
  • Trivitron Healthcare
  • OJ-Bio Ltd
  • Ortho-Clinical Diagnostics

The Point of Care Infectious Disease Testing Market size is expected to reach USD 28.51 Billion in 2034 from USD 18.42 Billion (2025) growing at a CAGR of 4.97% during 2026-2034.

The global point of care (POC) infectious disease testing market is poised for significant growth, driven by the increasing demand for rapid and accurate diagnostic solutions in the face of rising infectious diseases. The COVID-19 pandemic has underscored the critical need for timely testing to control outbreaks and manage public health effectively. POC testing offers the advantage of delivering results within minutes, enabling healthcare providers to make informed decisions quickly and initiate appropriate treatment. As the focus on early detection and prevention of infectious diseases intensifies, the adoption of POC testing solutions is expected to accelerate, fostering innovation and investment in this vital market.

Moreover, advancements in technology are set to transform the POC infectious disease testing landscape. The integration of molecular diagnostics, microfluidics, and biosensors is enhancing the sensitivity and specificity of tests, allowing for the detection of a wide range of pathogens, including bacteria, viruses, and parasites. Additionally, the development of user-friendly devices that can be operated in various settings, from clinics to remote locations, is expanding access to testing. As healthcare systems increasingly prioritize decentralized testing approaches, the demand for innovative POC solutions that can deliver accurate results in real-time will continue to rise.

In addition, the growing emphasis on personalized medicine and the increasing focus on global health initiatives are expected to shape the future of the POC infectious disease testing market . As healthcare providers seek to tailor treatments to individual patient needs, the demand for rapid diagnostic tools that can inform clinical decisions is becoming paramount. POC testing aligns with this trend by enabling healthcare professionals to quickly assess a patient's condition and adjust treatment plans accordingly. Furthermore, global health initiatives aimed at combating infectious diseases, particularly in low-resource settings, are driving investments in POC testing technologies that can be deployed in diverse environments. Collaborative efforts between diagnostic manufacturers, healthcare organizations, and public health agencies will be essential in advancing these solutions, ensuring that the POC infectious disease testing market remains agile and responsive to emerging health challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Technology

• Lateral Flow Immunoassay
• Agglutination Test
• Flow-Through Test/Immunoconcentration Assay
• Molecular Diagnostics
• Others

By Disease

• HIV POC
• Clostridium Difficile Poc
• HBV POC
• Pneumonia Or Streptococcus Associated Infections
• Respiratory Syncytial Virus (Rsv) POC
• HPV POC
• Influenza/Flu POC
• HCV POC
• MRSA POC
• TB & Drug-Resistant Tb Poc
• HSV POC
• Covid-19
• Others

By End Use

• Clinics
• Hospitals
• Home
• Assisted Living Healthcare Facilities
• Laboratory

COMPANIES PROFILED

• Abbott, Thermo Fisher Scientific Inc, F HoffmannLa Roche Ltd, Siemens Healthineers, Becton, Dickinson Company, Chembio Diagnostics Inc, Trinity Biotech, Cardinal Health, Quest Diagnostics Incorporated, BioRad Laboratories Inc, bioMrieux SA, Sight Diagnostics Ltd, Gene POC, Trivitron Healthcare, OJBio Ltd, OrthoClinical Diagnostics

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Technology
• 4.2. Lateral Flow Immunoassay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Agglutination Test Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Flow-Through Test/Immunoconcentration Assay Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Molecular Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY DISEASE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease
• 5.2. HIV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Clostridium Difficile Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. HBV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Pneumonia Or Streptococcus Associated Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Respiratory Syncytial Virus (Rsv) POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. HPV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Influenza/Flu POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. HCV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.10. MRSA POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.11. TB & Drug-Resistant Tb Poc Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.12. HSV POC Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.13. Covid-19 Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.14. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY END USE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End Use
• 6.2. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Home Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Assisted Living Healthcare Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Laboratory Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Technology
  • 7.2.2 By Disease
  • 7.2.3 By End Use
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Technology
  • 7.3.2 By Disease
  • 7.3.3 By End Use
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Technology
  • 7.4.2 By Disease
  • 7.4.3 By End Use
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Technology
  • 7.5.2 By Disease
  • 7.5.3 By End Use
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Technology
  • 7.6.2 By Disease
  • 7.6.3 By End Use
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL POINT OF CARE INFECTIOUS DISEASE TESTING INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Abbott
  • 9.2.2 Thermo Fisher Scientific Inc
  • 9.2.3 F. Hoffmann-La Roche Ltd
  • 9.2.4 Siemens Healthineers
  • 9.2.5 Becton
  • 9.2.6 Dickinson & Company
  • 9.2.7 Chembio Diagnostics Inc
  • 9.2.8 Trinity Biotech
  • 9.2.9 Cardinal Health
  • 9.2.10 Quest Diagnostics Incorporated
  • 9.2.11 Bio-Rad Laboratories Inc
  • 9.2.12 BioMAfA(C)Rieux SA
  • 9.2.13 Sight Diagnostics Ltd
  • 9.2.14 Gene POC
  • 9.2.15 Trivitron Healthcare
  • 9.2.16 OJ-Bio Ltd
  • 9.2.17 Ortho-Clinical Diagnostics